Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan
International Journal of Hematology · 2026-04 · 123 (4) · 556-569
DOI: 10.1007/s12185-025-04136-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Hematology, online erschienen am 24.12.2025. Verfasst von Hiroki Yamaguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Polyethylene Glycols, Polycythemia Vera, Interferon-alpha. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PharmaEssentia Japan.
Abstract (Originalsprache)
Objective
To verify the clinical benefit of ropeginterferon alfa-2b (ropegIFN) and evaluate its cost-effectiveness compared with hydroxycarbamide or ruxolitinib for patients with polycythemia vera (PV) under the National Health Insurance (NHI) system in Japan.
Methods
The cost-effectiveness of ropegIFN compared with hydroxycarbamide or ruxolitinib was evaluated for patients with PV requiring cytoreductive therapy (without prior cytoreductive therapy) and resistant or intolerant to hydroxycarbamide. According to previous reports, patients with PV who achieve a molecular response with a JAK 2V617F allele burden < 10% tend to maintain hematologic responses even after discontinuing interferon treatment. Therefore, in these analyses, patients who achieved a molecular response with JAK 2V617F burden < 10% discontinued ropegIFN treatment.
Results
Compared with hydroxycarbamide, ropegIFN yielded an incremental effectiveness of 0.440 quality-adjusted life years (QALYs), indicating a higher QALY gain. The incremental costs were 128,001,730 yen, and the incremental cost-effectiveness ratio (ICER) was 291,092,030 yen/QALY. Compared with ruxolitinib, the incremental effectiveness of ropegIFN was 1.278 QALYs, while the total costs were reduced by 18,025,182 yen, which resulted in a dominant ICER.
Conclusions
These results suggest that ropegIFN may be cost-effective compared with ruxolitinib in patients with PV who are resistant or intolerant to hydroxycarbamide under the NHI system in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nippon Medical School, Tokyo, Japan.
- Department of Hematology and Oncology, Mie University, Mie, Japan.
- Department of Hematology, Tokyo Medical University, Tokyo, Japan.
- Department of Hematology, Sapporo Hokuyu Hospital, Hokkaido, Japan.
- PharmaEssentia Japan KK, Akasaka Center Building 12Th FI, 1-3-13 Motoakasaka, Minato-Ku, Tokyo, 107-0051, Japan. hiromi_igari@pharmaessentia.com.
- CRECON Medical Assessment Inc, Tokyo, Japan.
Förderung
- PharmaEssentia Japan
Zitieren
APA
Yamaguchi, H., Sugimoto, Y., Gotoh, A., Ota, S., Igari, H., Murata, T., Hanada, K., Komatsu, N., & Kirito, K. (2026). Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan. International Journal of Hematology, 123(4), 556-569. https://doi.org/10.1007/s12185-025-04136-4
Vancouver
Yamaguchi H, Sugimoto Y, Gotoh A, Ota S, Igari H, Murata T, et al. Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan. International Journal of Hematology. 2026;123(4):556-569. doi:10.1007/s12185-025-04136-4
BibTeX
@article{Yamaguchi2026,
author = {Yamaguchi, Hiroki and Sugimoto, Yuka and Gotoh, Akihiko and Ota, Shuichi and Igari, Hiromi and Murata, Tatsunori and Hanada, Keigo and Komatsu, Norio and Kirito, Keita},
title = {Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan},
journal = {International Journal of Hematology},
year = {2026},
volume = {123},
number = {4},
pages = {556--569},
doi = {10.1007/s12185-025-04136-4}
}
EUVIMED